Adelaide, Australia – GenesisCare has today announced the availability of a state-first cutting-edge treatment option for South Australians living with prostate cancer, significantly reducing the number of visits required to hospital.
Stereotactic ablative radiation therapy (known as SABR) is a highly accurate, non-invasive type of radiation therapy that targets both the tumour’s connective tissue and DNA, helping to rapidly kill the cancer cells.
GenesisCare Radiation Oncologist, Dr Marcus Dreosti, said: “SABR enables us to deliver treatment across five sessions, compared to the 20-40 sessions required with conventional radiation therapy, significantly reducing the physical and emotional burden of treatment for our patients.”
“SABR allows clinicians to precisely deliver a high dose of radiation directly to the tumour with sub-millimetre accuracy, destroying cancer cells while preserving surrounding healthy tissues.”
“This is especially important for cancers located near other sensitive organs, such as prostate cancer, as it can help to protect the healthy cells and minimise side effects.”
Prostate cancer is the state’s most diagnosed cancer in men, accounting for 28.5% of all male cancers and 12% of all cancer deaths.
For approximately 50 per cent of all cancer patients, radiation therapy plays an important role in the treatment pathway, used with curative intent and in pain and symptom management.
“Multiple international prospective trials confirm stereotactic ablative radiation therapy for low and intermediate risk prostate cancer is effective in reducing the risk of recurrence and is associated with minimal slide effects,” said Dr Dreosti.
GenesisCare General Manager of Oncology in South Australia, Duy Tran, said: “GenesisCare is delighted to be at the forefront of bringing this innovative new treatment option to South Australia, which will allow patients to spend more time at home with their loved ones.”
“GenesisCare is steadfastly committed to ensuring men across South Australia receive rapid access to the latest advancements in treatments for prostate cancer and the best possible life outcomes.
“This new shorter treatment option is particularly beneficial for prostate cancer patients living in regional South Australia, who would have previously had to spend up to 6 weeks away from their families and livelihoods.”
Prostate cancer patients will now have access to this new treatment option at GenesisCare’s Tennyson Centre at Kurralta Park.
Prostate cancer patients undergoing SABR treatment will also have access to a prostate cancer specialist nurse who will provide care and support to men and their families throughout their entire journey, from diagnosis, through to treatment, side effect management and after care.